Genmab — April 2016
-
2 A conditional marketing authorisation is granted to a medicinal product that fulfils an unmet medical need when the benefit
to public health of immediate availability outweighs the risk inherent in the fact that additional data are still required. The
marketing authorisation holder is likely to provide comprehensive clinical data at a later stage. -
Det er ok Bulder.
-
Endelig godkendelse inden for 67 dage
-
Det er da hurtigt.
-
Lancering i juni eller juli i de første EU markeder
-
Men ikke hurtigt nok for patienterne.
-
Nordea har indregnet USD 67m i salg i 2016 til EU lande
-
Vi kommer i følge Jan hurtigt ud i Tyskland, men den andre lande tager længere tid.
-
Jeg præsenterer Genmab og er ordstyrer på deres præsentation på Investordagen d. 12. april i København. Jeg skaffer et link til gratis adgang til alle fra PI. Det lægger jeg ud på mandag.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind